“The FDA’s Fast Track designation for the investigation of BXCL701 in SCNC is an important recognition of our most advanced immuno-oncology asset and an acknowledgment of its potential to address the considerable unmet medical need in these patients. At the same time, it further validates the unique AI-based drug re-innovation approach that we used to discover this asset,”
ok median OS is 15.5 months instead of 9.6, but still a promising path...
Neuroendocrine prostate cancer
Seviteronel (VT-464) - Durham's Innocrin Nabs FDA Fast Track OK for Prostate Cancer Drug
Neuroendocrine Prostate Cancer mLiver c
Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Neuroendocrine vs small cell
